Momenta Pharmaceuticals, Inc. Study Showing M402 Inhibits Tumor Metastasis in Multiple Murine Oncology Models Published in PLoS One

CAMBRIDGE, Mass., June 20, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that results from a preclinical study of its novel oncology drug candidate, M402, were published in the on-line edition of the journal PLoS ONE (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0021106). PLoS One is the online edition of the scientific journal Public Library of Science. M402 is a heparan sulfate glycosaminoglycan (HSGAG) mimetic engineered from low molecular weight heparin (LMWH) to have potent activity against multiple factors involved in tumor angiogenesis, progression and metastasis while displaying highly reduced anticoagulant activity.

Back to news